Cefditoren: a clinical overview

被引:1
作者
Giuliano, Simone [1 ]
Acquasanta, Angela [1 ]
Martini, Luca [1 ]
Sbrana, Francesco [2 ]
Flammini, Sarah [1 ]
Tascini, Carlo [1 ,3 ]
机构
[1] Azienda Sanit Univ Friuli Cent ASUFC, Infect Dis Clin, Udine, Italy
[2] Fdn Toscana Gabriele Monasterio, Reference Ctr Diag & Treatment Inherited Dyslipide, Lipoapheresis Unit, Pisa, Italy
[3] Univ Udine, Dept Med Area DAME, Udine, Italy
关键词
Cefditoren; Clinical indications; Pharmacodynamic; Pharmacokinetics; RESPIRATORY-TRACT INFECTIONS; RHINOSINUSITIS; MANAGEMENT; RESISTANCE; FAECALIS; INVITRO; TIME;
D O I
暂无
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Cefditoren is an oral third-generation cephalosporin with a large spectrum activity against Gram-negative and Gram-positive bacteria which are reported to be responsible for respiratory tract and skin and skin structure infections. In this work we reviewed the pharmacodynamics, pharmacokinetics, and the main clinical indications of cefditoren. Similarly to other beta-lactams, cefditoren is a time-dependent antibiotic, and its "best " PK/PD target is probably 40% dosing interval time > 4-5-fold MIC and 40-70% dosing interval time > 4-5-fold MIC for bacteriostatic and bactericidal effect, respectively. In fasting patients oral bioavailability is low and increases when the drug is taken with food. This cephalosporin has significant bactericidal activity against S. pneumoniae (both penicillin-susceptible and penicillin-resistant strains), S. pyogenes, H. Influenzae and M. catarrhalis, as well as methicillin-susceptible S. aureus (MSSA). Regarding Enterobacterales, cefditoren has very low MICs90 against K. pneumoniae andE. coli but is not active against AmpC-, ESBL-and carbapenemase-producer' strains. Licensed indications are treatment of exacerbations of chronic bronchitis,acute rhinosinusitis, otitis media, upper respiratory tract infections (pharyngitis/tonsillitis), lower community-acquired respiratory tract infections (LRTIs), and skin and skin-structure infections (SSTI). Cefditoren might have a role in switching from parenteral to oral therapy in acute pyelonephritis and LRTIs. with a reduction of adverse effects and hospital costs. Eventually, due to its supposed binding to enterococcal penicillin binding proteins (PBPs) cefditoren, in combination with other beta-lactams, might have a role in partial oral enterococcal endocarditis treatment..
引用
收藏
页码:9 / 17
页数:9
相关论文
共 51 条
[1]  
[Anonymous], 2000, Otolaryngol Head Neck Surg, V123, P5
[2]   Microbiology of acute otitis media in Costa Rican children [J].
Arguedas, A ;
Loaiza, C ;
Perez, A ;
Vargas, F ;
Herrera, M ;
Rodriguez, G ;
Gutierrez, A ;
Mohs, E .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (08) :680-684
[3]   INVITRO ACTIVITY OF CEFPROZIL (BMY-28100) AND LORACARBEF (LY-163892) AGAINST PATHOGENS OBTAINED FROM MIDDLE-EAR FLUID [J].
ARGUEDAS, AG ;
ARRIETA, AC ;
STUTMAN, HR ;
AKANIRO, JC ;
MARKS, MI .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 (03) :311-318
[4]   Clinical efficacy of amoxicillin/clavulanate plus cefditoren as de-escalation combination therapy for endocarditis due to strongly biofilm-forming Enterococcus faecalis [J].
Attanasio, Vittorio ;
Di Luca, Mariagrazia ;
Carozza, Antonio ;
Severino, Sergio ;
Pallotto, Carlo ;
Capoluongo, Nicolina ;
Palmiero, Giulia ;
Bernardo, Mariano ;
Tascini, Carlo .
INFECTIOUS DISEASES, 2020, 52 (05) :376-379
[5]   Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications A Scientific Statement for Healthcare Professionals From the American Heart Association [J].
Baddour, Larry M. ;
Wilson, Walter R. ;
Bayer, Arnold S. ;
Fowler, Vance G., Jr. ;
Tleyjeh, Imad M. ;
Rybak, Michael J. ;
Barsic, Bruno ;
Lockhart, Peter B. ;
Gewitz, Michael H. ;
Levison, Matthew E. ;
Bolger, Ann F. ;
Steckelberg, James M. ;
Baltimore, Robert S. ;
Fink, Anne M. ;
O'Gara, Patrick ;
Taubert, Kathryn A. .
CIRCULATION, 2015, 132 (15) :1435-1486
[6]  
Barberán MT, 2008, REV ESP QUIM, V21, P45
[7]   Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations [J].
Biedenbach, Douglas J. ;
Jones, Ronald N. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2009, 64 (02) :202-212
[8]   Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007) [J].
Biedenbach, Douglas J. ;
Jones, Ronald N. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2009, 64 (02) :177-184
[9]   Role of the Oral Beta-Lactams in the Treatment of Exacerbations of Chronic Bronchitis: Critical Analysis and Therapeutic Recommendations [J].
Blasi, F. ;
Concia, E. ;
Mazzei, T. ;
Moretti, A. M. ;
Nicoletti, G. ;
Novelli, A. ;
Tempera, G. .
JOURNAL OF CHEMOTHERAPY, 2010, 22 :3-28
[10]   Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication [J].
Blasi, Francesco ;
Tarsia, Paolo ;
Mantero, Marco ;
Morlacchi, Letizia C. ;
Piffer, Federico .
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2013, 9 :55-64